Skip to main content

Table 1 Demographic and Baseline Characteristicsa

From: Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial

Parameter CCH 0.25 mg
(n = 22)
CCH 0.40 mg
(n = 18)
CCH 0.60 mg
(n = 18)
Placebo
(n = 17)
Mean age, y (SD) 57.9 (10.0) 58.1 (12.4) 60.0 (10.2) 59.9 (8.8)
Sex, n (%)
 Female 11 (50.0) 10 (55.6) 6 (33.3) 7 (41.2)
 Male 11 (50.0) 8 (44.4) 12 (66.7) 10 (58.8)
Race, n (%)
 White 22 (100.0) 17 (94.4) 18 (100.0) 17 (100.0)
 Other 0 1 (5.6) 0 0
Mean age at Dupuytren disease onset, y (SD) 51.6 (13.5) 50.4 (13.8) 55.8 (8.3) 54.7 (11.2)
Nodules on selected hand, n (%)
 1 9 (40.9) 9 (50.0) 10 (55.6) 6 (35.3)
 2 6 (27.3) 3 (16.7) 4 (22.2) 5 (29.4)
 ≥ 3 7 (31.8) 6 (33.3) 4 (22.2) 6 (35.3)
Mean nodule areab, cm2 (SD) 0.7 (0.3) 0.7 (0.4) 0.7 (0.3) 0.8 (0.4)
Prior Dupuytren disease treatments
 None 19 (86.4) 18 (100.0) 16 (88.9) 17 (100.0)
 Fasciectomy 2 (9.1) 0 0 0
 Needle aponeurotomy 0 0 1 (5.6) 0
 CCH 1 (4.5) 0 2 (11.1) 0
  1. aSafety population (n = 75)
  2. bMeasured using calipers. Calculated as 0.79 × length × width
  3. CCH collagenase clostridium histolyticum, SD standard deviation
\